Real-World Physician Experience on the Effectiveness of WillfortTM Drops in Anemic Patients: A Post-Marketing Survey
(Advancements in Homeopathic Research, Vol. 11 No.2, May 2026-July 2026, Date of Publication 2026/05/01, Pages no. 20-25 ISSN : 2456-3668 (Print) // EISSN : 2583-5661 (Online) DOI : 10.48165/ ahr.2026.11.2.2)
Dr. Poorva Tiwari1, Dr. Snigdha Suman Dalua1, Dr. Praveen Saxena2, Dr. Ramachandran Valavan3*
1. Scientific & Medical Affairs Department; Dr. Willmar Schwabe India Pvt. Ltd.
2. Marketing Department; Dr. Willmar Schwabe India Pvt. Ltd.
3*. Scientific, Medical & Regulatory Department; Dr. Willmar Schwabe India Pvt Ltd
Corresponding Author:
Dr. Ramachandran Valavan
MD (Hom), MBA, PhD, Head – Scientific, Medical & Regulatory Affairs,
Mobile: +91 93123 09186,
Email: dr.valavan@schwabeindia.com./
drvalavan@yahoo.com
Abstract
Introduction: Anemia is a highly prevalent hematological condition associated with fatigue, weakness, pallor, reduced stamina, impaired concentration, and diminished quality of life. Despite the availability of conventional therapies, concerns regarding compliance, and recurrence have increased interest in integrative supportive approaches. The present study aimed to evaluate the real-world effectiveness, speed of action, and physician recommendation of WillfortTM in the management of anemia-associated symptoms.
Methods & Methods: A structured Microsoft Forms survey was designed to collect feedback from the market (Consumers, Pharmacist & Physicians). The questionnaire assessed speed of action, and clinical effectiveness using a 5-point rating scale, and recommendation patterns. Overall the data was obtained from 53 respondents. Out of this, 46 are prescribing physicians, others being whose responses were taken into consideration for descriptive analysis.
Results: Regarding speed of action, 30.4% of physicians reported immediate improvement (score 5), while 26.1% observed symptomatic benefit within 15 days (score 4); overall, 80.4% reported improvement within 4 weeks. In terms of effectiveness, 47.8% of physicians assigned the highest rating of 5, and 34.8% rated the formulation 4; overall, 82.6% rated the product 4 or 5, indicating positive therapeutic benefit. Additionally, 95.7% of physicians expressed willingness to recommend the formulation to fellow practitioners, reflecting substantial clinical confidence in its utility for anemia-associated complaints.
Conclusion: Real-world physician feedback suggests that WillfortTM is clinically useful and immensely beneficial in symptomatic improvement of anemia-associated conditions in routine practice. The findings confirm its potential role as a supportive integrative formulation for managing fatigue, weakness, pallor, reduced stamina, and related constitutional symptoms. Further prospective controlled clinical studies with objective hematological parameters are warranted to strengthen the evidence base.
ISSN – 2456-3668 (P) * EISSN – 2583-5661 (O) * VOL. 11 NO. 2 May 2026-July 2026, (pp. 20-25) DOI : 10.48165/ ahr.2026.11.2.2
